| Principal Amount USD ($) | Value | |||||
| UNAFFILIATED ISSUERS — 102.1% | ||||||
| Corporate Bonds — 0.0% of Net Assets | ||||||
| Pharmaceuticals — 0.0% | ||||||
| 2,600,000(a)+ | Tricida, Inc., 5/15/27 | $ — | ||||
| Total Pharmaceuticals | $— | |||||
| Total Corporate Bonds (Cost $0) | $— | |||||
| Face Amount USD ($) | ||||||
| Insurance-Linked Securities—3.2% of Net Assets# | ||||||
| Reinsurance Sidecars — 3.2% | ||||||
| Multiperil – Worldwide — 3.2% | ||||||
| 40,466(b)+ | Alturas Re 2022-2, 12/31/27 | $ 486 | ||||
| 750,000(c)(d)+ | Gleneagles Re 2022, 12/31/27 | — | ||||
| 1,500,000(b)+ | Thopas Re 2022, 12/31/27 | 9,420 | ||||
| 1,596,147(b)+ | Thopas Re 2023, 12/31/28 | — | ||||
| 1,596,147(b)+ | Thopas Re 2024, 12/31/29 | 8,990 | ||||
| 1,000,000(b)+ | Thopas Re 2025, 12/31/30 | 54,300 | ||||
| $73,196 | ||||||
| Total Reinsurance Sidecars | $73,196 | |||||
| Total Insurance-Linked Securities (Cost $289,233) | $73,196 | |||||
| Principal Amount USD ($) | ||||||
| Foreign Government Bond — 0.0% of Net Assets | ||||||
| Russia — 0.0% | ||||||
| 382,800(a)+# | Russian Government International Bond, 7.500%, 3/31/30 | $ — | ||||
| Total Russia | $— | |||||
| Total Foreign Government Bond (Cost $338,124) | $— | |||||
| Shares | Value | |||||
| SHORT TERM INVESTMENTS — 98.9% of Net Assets | ||||||
| Open-End Fund — 98.9% | ||||||
| 2,251,957(e) | Dreyfus Government Cash Management, Institutional Shares, 3.54% | $2,251,957 | ||||
| $2,251,957 | ||||||
| TOTAL SHORT TERM INVESTMENTS (Cost $2,251,957) | $2,251,957 | |||||
| TOTAL INVESTMENTS IN UNAFFILIATED ISSUERS — 102.1% (Cost $2,879,314) | $2,325,153 | |||||
| OTHER ASSETS AND LIABILITIES — (2.1)% | $(47,328) | |||||
| net assets — 100.0% | $2,277,825 | |||||
| (a) | Security is in default. |
| (b) | Issued as preference shares. |
| (c) | Non-income producing security. |
| (d) | Issued as participation notes. |
| (e) | Rate periodically changes. Rate disclosed is the 7-day yield at June 30, 2026. |
| + | Security is valued using significant unobservable inputs (Level 3). |
| * | The Fund is in the process of liquidating its assets pursuant to the Plan of Liquidation and Dissolution approved by stockholders at a meeting originally scheduled for July 17, 2025 and adjourned to August 20, 2025. Information shown in the Schedule of Investments reflects remaining investments held by the Fund at June 30, 2026. |
| # | Securities are restricted as to resale. |
| Restricted Securities | Acquisition date | Cost | Value |
| Alturas Re 2022-2 | 4/11/2023 | $— | $486 |
| Gleneagles Re 2022 | 1/18/2022 | 289,233 | — |
| Russian Government International Bond | 6/26/2002 | 338,124 | — |
| Thopas Re 2022 | 2/7/2022 | — | 9,420 |
| Thopas Re 2023 | 2/15/2023 | — | — |
| Thopas Re 2024 | 2/2/2024 | — | 8,990 |
| Thopas Re 2025 | 1/10/2025 | — | 54,300 |
| Total Restricted Securities | $73,196 | ||
| % of Net assets | 3.2% |
| Level 1 | – | unadjusted quoted prices in active markets for identical securities. |
| Level 2 | – | other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risks, etc.). |
| Level 3 | – | significant unobservable inputs (including the Adviser’s own assumptions in determining fair value of investments). |
| Level 1 | Level 2 | Level 3 | Total | |
| Corporate Bonds | $— | $— | $—* | $—* |
| Insurance-Linked Securities | ||||
| Reinsurance Sidecars | ||||
| Multiperil – Worldwide | — | — | 73,196 | 73,196 |
| Foreign Government Bond | — | — | —* | —* |
| Open-End Fund | 2,251,957 | — | — | 2,251,957 |
| Total Investments in Securities | $2,251,957 | $— | $73,196 | $2,325,153 |
| * | Securities valued at $0. |
| Common Stocks | Convertible Corporate Bonds | Corporate Bonds | Insurance- Linked Securities | Foreign Government Bond | Total | |
| Balance as of 3/31/26 | $0* | $0* | $0* | $92,330 | $0* | $92,330 |
| Realized gain (loss) | (8) | (103,505) | — | — | — | (103,513) |
| Changed in unrealized appreciation (depreciation) | 8 | 103,505 | — | (19,134) | (2,391) | 81,988 |
| Return of capital | — | — | — | — | 2,391 | 2,391 |
| Purchases | — | — | — | — | — | — |
| Sales | — | (0)* | — | — | — | (0)* |
| Transfers in to Level 3** | — | — | — | — | — | — |
| Transfers out of Level 3** | — | — | — | — | — | — |
| Balance as of 6/30/26 | $0 | $0 | $0* | $73,196 | $0* | $73,196 |
| * | Securities valued at $0 | ||
| ** | Transfers are calculated on the beginning of period values. During the period ended June 30, 2026, there were no transfers in or out of Level 3. | ||
| Net change in unrealized appreciation (depreciation) of Level 3 investments still held and considered Level 3 at June 30, 2026: | $(21,525) | ||